Michael Popiolek
8PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Jun 18, 2024
Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M4 Muscarinic Acetylcholine Receptor.Christopher R Butler, Michael Popiolek, Laura A McAllister
|Jan 24, 2020
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects.Damon Young, Michael Popiolek, Patrick Trapa
|Nov 28, 2018
Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.Catherine A Thorn, Joshua Moon, Clinton A Bourbonais
|Oct 19, 2018
In Vivo Modulation of Hippocampal Excitability by M4 Muscarinic Acetylcholine Receptor Activator: Implications for Treatment of Alzheimer's Disease and Schizophrenic Patients.Michael Popiolek, Yael Mandelblat-Cerf, Damon Young
|Jun 13, 2018
Lack of Effect of Sodium Benzoate at Reported Clinical Therapeutic Concentration on d-Alanine Metabolism in Dogs.Michael Popiolek, Brendan Tierney, Stefanus J Steyn
|Jun 10, 2017
Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity.Jennifer E Davoren, Michelle Garnsey, Betty Pettersen
Pageof 2
